|TYO : 4588|
|10,739 million yen|
We are a drug discovery bio-venture that operates on an R&D-first basis. We develop and commercialise highly original viral gene-modified cancer drugs, drugs for treating severe infectious diseases and cancer testing drugs.
We aim to grow as a ‘viral drug discovery company’. Our pipeline comprises the ‘oncology’ area, covering everything from cancer detection to treatment, and the ‘severe infectious diseases’ area, centred on OBP-2011, a therapy for novel coronavirus infections. In the oncology area, we have the therapeutic telomelysin, the next-generation telomelysin OBP-702 and telomescan for the early detection or prediction of cancer recurrence.